Presidio, Boehringer join forces for hep C drug combo trial

03/14/2013 | American City Business Journals

Presidio Pharmaceuticals and Boehringer Ingelheim agreed to collaborate in a midstage clinical study of an interferon-free, combination therapy for hepatitis C. The trial, which will start next quarter, will evaluate Presidio's PPI-668, in combination with Boehringer's protease inhibitors BI201335 and BI207127.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA